scholarly journals Use of Accessible Blood Filter for Post-operative Cell Salvage in Cardiac Surgery

2021 ◽  
pp. 1-3
Author(s):  
Rosita Bihariesingh ◽  
Rosita Bihariesingh ◽  
Pieter Voigt ◽  
Rakesh Bansie
Keyword(s):  
Red Blood Cell Transfusion ◽  
Cell Salvage ◽  
Blood Products ◽  
Donor Blood ◽  
Clinical Value ◽  
Intraoperative Cell Salvage ◽  
Blood Filter ◽  
The Poor ◽  
Resource Setting ◽  
Severe Coagulopathy

The availability of centrifugal cell savers supports intraoperative cell salvage and thereby reduces the need for allogeneic red blood cell transfusion. Use of these devices, however, is limited to the operating room, forcing a switch to allogeneic products in the post-operative setting. Here we present a case of massive post-operative bleeding due to severe coagulopathy following CABG. Due to the lack of availability of donor blood products a novel blood filter (HemoClear BV, Zwolle, the Netherlands) was used for post-operative salvage. Because of its accessible use, we believe this salvage device has great clinical value in the poor-resource setting.

scholarly journals Trial of intraoperative cell salvage versus transfusion in ovarian cancer (TIC TOC): protocol for a randomised controlled feasibility study

BMJ Open ◽  
2018 ◽  
Vol 8 (11) ◽  
pp. e024108 ◽  
Author(s):  
Khadra Galaal ◽  
Alberto Lopes ◽  
Colin Pritchard ◽  
Andrew Barton ◽  
Jennifer Wingham ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Blood Transfusion ◽  
Controlled Trial ◽  
Cancer Surgery ◽  
Conservation Strategy ◽  
Adult Women ◽  
Cell Salvage ◽  
Donor Blood ◽  
Intraoperative Cell Salvage ◽  
Randomised Controlled

IntroductionOvarian cancer is the leading cause of death from gynaecological cancer, with more than 7000 new cases registered in the UK in 2014. In patients suitable for surgery, the National Institute of Health and Care Excellence guidance for treatment recommends surgical resection of all macroscopic tumour, followed by chemotherapy. The surgical procedure can be extensive and associated with substantial blood loss which is conventionally replaced with a donor blood transfusion. While often necessary and lifesaving, the use of donor blood is associated with increased risks of complications and adverse surgical outcomes. Intraoperative cell salvage (ICS) is a blood conservation strategy in which red cells collected from blood lost during surgery are returned to the patient thus minimising the use of donor blood. This is the protocol for a feasibility randomised controlled trial with an embedded qualitative study and feasibility economic evaluation. If feasible, a later definitive trial will test the effectiveness and cost-effectiveness of ICS reinfusion versus donor blood transfusion in ovarian cancer surgery.Methods and analysisSixty adult women scheduled for primary or interval ovarian cancer surgery at participating UK National Health Service Trusts will be recruited and individually randomised in a 1:1 ratio to receive ICS reinfusion or donor blood (as required) during surgery. Participants will be followed up by telephone at 30 days postoperatively for adverse events monitoring and by postal questionnaire at 6 weeks and 3 monthly thereafter, to capture quality of life and resource use data. Qualitative interviews will capture participants’ and clinicians’ experiences of the study.Ethics and disseminationThis study has been granted ethical approval by the South West–Exeter Research Ethics Committee (ref: 16/SW/0256). Results will be disseminated via peer-reviewed publications and will inform the design of a larger trial.Trial registration numberISRCTN19517317.

scholarly journals Gambaran Hasil Pemeriksaan HIV pada Darah Donor

2021 ◽  
Vol 2 (1) ◽  
pp. 46-50
Author(s):  
Bagus Triatmojo
Keyword(s):  
Blood Transfusion ◽  
Age Groups ◽  
Blood Type ◽  
Blood Products ◽  
Blood Safety ◽  
Elisa Method ◽  
Donor Blood ◽  
Voluntary Donor ◽  
Filter Test ◽  
Research Type

HIV cases in Jepara District in recent years have demanded the handling of several aspects simultaneously including the Blood Transfusion Unit (BTU). HIV can be transmitted through blood transfusion or other blood products. BTU of PMI Jepara Regency carries out recruitment of voluntary donor from Jepara society. The HIV examination as part of an IMLTD screening test is done for safety of donor blood. The HIV examination in all donor blood uses rapid and elisa method. Examination results are stated as reactive and non reactive. Research objective to find out the description of HIV examination results in donor blood at the BTU of PMI Kabupaten Jepara in 2019. Research method the research type was descriptive using records of donor data at BTU of PMI Kabupaten Jepara in 2019. The examination results of reactive HIV in 12 donor blood (0,08%). non-reactive blood donor of HIV  in age groups 18 years, 18-24, 25-44, 45-59, and ≥ 60 years respectively 9,55%, 22,39%, 51,75%, 16,01% and 0,21%. Reactive HIV in age groups 18-24, 25-44, and 45-59 years were 0,034%, 0,034%, and 0,13%. Non-reactive HIV in men 68,22% and in women 31,70%. Reactive HIV in men 0,07%, and women 0,01%. Non-reactive HIV in voluntary donor blood was 99,779% and substitute donor was 0,127%. HIV of reactive voluntary donor blood was 0,074%, and substitute donor was 0,007%. HIV filter test is indispensable for blood safety because the age, gender and blood type of donors have the potential for reactive HIV.

A Child has a Right to Blood Transfusion Services in Nigeria, despite the Religious Status of the Parents or Guardians

2021 ◽  
Vol 4 (4) ◽  
Author(s):  
Uchejeso M Obeta
Keyword(s):  
Intensive Care ◽  
Blood Transfusion ◽  
Blood Cell ◽  
Neonatal Intensive Care ◽  
Healthcare Providers ◽  
Red Blood Cell Transfusion ◽  
Blood Transfusions ◽  
Blood Products ◽  
Serious Illness ◽  
Life Saving

Red blood cell transfusion is an important and frequent component of neonatal intensive care. Whereas blood and blood products transfusion can help a patient (child) recover from a serious illness, surgery or injury, because of the religious beliefs of some parents or guardians, a child may be denied the benefit of this life-saving service. Several legal statutes and precedents exist to protect the rights of children in need of life-saving blood transfusions where denied this opportunity to be transfused and survive. The awareness of these extant laws and statutes are critical for the empowerment of healthcare providers in the performance of their role within the provisions of the law and medical ethics.

scholarly journals Biologic effects of leukocytes present in transfused cellular blood products

Blood ◽  
1994 ◽  
Vol 84 (6) ◽  
pp. 1703-1721 ◽  
Author(s):  
JO Bordin ◽  
NM Heddle ◽  
MA Blajchman
Keyword(s):  
Clinical Trials ◽  
Adverse Effects ◽  
Bone Marrow Failure ◽  
Blood Components ◽  
Blood Products ◽  
Clinical Value ◽  
Leukocyte Depletion ◽  
Biologic Effects ◽  
Bowel Diseases ◽  
Leukocyte Number

Abstract A considerable literature has accumulated over the past decade indicating that leukocytes present in allogeneic cellular blood components, intended for transfusion, are associated with adverse effects to the recipient. These include the development of febrile transfusion reactions, graft-versus-host disease, alloimmunization to leukocyte antigens, and the immunomodulatory effects that might influence the prognosis of patients with a malignancy. Moreover, it has become evident that such leukocytes may be the vector of infectious agents such as CMV, HTLV-I/II, and EBV as well as other viruses. An interesting development that has occurred coincidentally in transfusion medicine is that agencies responsible for the provision of blood products are being designated manufacturers of biologicals. The trend among manufacturers of biologicals is to try to produce pure products to provide for the specific therapeutic need of patients. Thus, with the realization that allogeneic leukocytes and their products may have adverse biologic activities, there is increasing pressure from various sources for the reduction of the leukocyte content in allogeneic blood components to minimize the occurrence of their adverse effects. Although the threshold leukocyte number below which these effects might no longer occur is still to be determined, a 2 to 3 log10 leukocyte reduction, provided by the currently available commercial leukocyte filters, has been shown to reduce the frequency of many of such reactions. On the other hand, the immunosuppressive effects produced by the infusion of allogeneic leukocytes might be beneficial for some patients, ie, for the maintenance of kidney allografts, in possibly reducing the relapse rate in patients with inflammatory bowel diseases, and in ameliorating recurrent spontaneous abortion. Moreover, therapeutic granulocyte transfusions may be of benefit in certain well- defined categories of patients infected with bacteria, yeast, and/or fungi. These include neonates with bacterial sepsis associated with bone marrow failure as well as severely neutropenic leukemic patients with an infection unresponsive to appropriate and specific antibiotic therapy. Many of the results obtained with the use of leukocyte depletion filters are tantalizing, but the actual clinical benefit of leukodepletion has not been established in most instances, because much of the available data are retrospective or from uncontrolled clinical trials. Moreover, issues of cost-effectiveness and quality control have not been considered adequately. Properly designed prospective clinical trials are essential to provide data with which to answer such questions and also to help define the optimal conditions required for the preparation of blood components ultimately destined for clinical use. Only with the availability of such data can sound decisions be made about the clinical value of leukodepletion.

scholarly journals Economic analysis of the implementation of autologous transfusion technologies throughout England

2005 ◽  
Vol 21 (2) ◽  
pp. 234-239 ◽  
Author(s):  
Simon Dixon ◽  
Virge James ◽  
Daniel Hind ◽  
Craig J. Currie
Keyword(s):  
Policy Development ◽  
Large Scale ◽  
Future Research ◽  
Cell Salvage ◽  
Autologous Transfusion ◽  
The United Kingdom ◽  
Intraoperative Cell Salvage ◽  
The Mean ◽  
The Cost ◽  
Preoperative Autologous Donation

Objectives:This study aims to provide the first estimates of the costs and effects of the large scale introduction of autologous transfusion technologies into the United Kingdom National Health Service.Methods:A model was constructed to allow disparate data sources to be combined to produce estimates of the scale, costs, and effects of introducing four interventions. The interventions considered were preparing patients for surgery (PPS) clinics, preoperative autologous donation (PAD), intraoperative cell salvage (ICS), and postoperative cell salvage (PoCS).Results:The key determinants of cost per operation are the anticipated level of reductions in blood use, the mean level of blood use, mean length of stay, and the cost of the technology. The results show the potential for considerable reductions in blood use. The greatest reductions are anticipated to be through the use of PPS and ICS. Vascular surgery, transplant surgery, and cardiothoracic surgery appear to be the specialties that will benefit most from the technologies.Conclusions:Several simplifications were used in the production of these estimates; consequently, caution should be used in their interpretation and use. Despite the drawbacks in the methods used in the study, the model shows the scale of the issue, the importance of gathering better data, and the form that data must take. Such preliminary modeling exercises are essential for rational policy development and to direct future research and discussion among stakeholders.

Sign in / Sign up

Export Citation Format

Share Document